Choose XBONZY^®:

a biosimilar that delivers quality and improved access,
so you can prescribe with confidence^{1, 2}

XBONZY^® matches the reference product in key characteristics:³

• Same indications³
  • Prevention of skeletal-related events^* in adults with advanced malignancies involving bone.
    ^*Pathological fracture, radiation to bone, spinal cord compression or surgery to bone.
  • Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

  

• Same dosage form³
• Same mode of action³